Merck & Co notches up another lung cancer use for KeytrudaBristol-Myers Squibb’s immunotherapy Opdivo has new competition in small cell lung cancer (SCLC) after the FDA approved its Share XMerck & Co notches up another lung cancer use for Keytrudahttps://pharmaphorum.com/news/merck-co-notches-up-another-lung-cancer-use-for-keytruda/
AZ sees triple approval in Japan for cancer and COPD drugsAstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its Share XAZ sees triple approval in Japan for cancer and COPD drugshttps://pharmaphorum.com/news/az-sees-triple-approval-in-japan-lynparza/
Three drugmakers challenge Trump’s price disclosure rulingAmgen, Merck & Co and Eli Lilly have launched a legal challenge to a new rule that will Share XThree drugmakers challenge Trump’s price disclosure rulinghttps://pharmaphorum.com/news/three-drugmakers-challenge-trumps-price-disclosure-ruling/
Merck bolts on another immunology firm with $773m Tilos dealMerck & Co/MSD has agreed to buy privately held biotech Tilos Therapeutics for up to $773 million, its Share XMerck bolts on another immunology firm with $773m Tilos dealhttps://pharmaphorum.com/news/merck-bolts-on-another-immunology-firm-with-773m-tilos-deal/
AZ/Merck & Co wow ASCO with pancreatic cancer dataFinding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the Share XAZ/Merck & Co wow ASCO with pancreatic cancer datahttps://pharmaphorum.com/news/az-merck-co-wow-asco-with-pancreatic-cancer-data/
AZ/Merck & Co reveal data supporting PARP drug in prostate cancerPARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest Share XAZ/Merck & Co reveal data supporting PARP drug in prostate cancerhttps://pharmaphorum.com/news/az-merck-co-reveal-data-supporting-parp-drug-in-prostate-cancer/
Merck & Co to buy cancer biotech Peloton for $2.2bnMerck & Co is to buy the privately-held biotech Peloton for up to $2.2 billion, adding further oncology Share XMerck & Co to buy cancer biotech Peloton for $2.2bnhttps://pharmaphorum.com/news/merck-co-to-buy-cancer-biotech-peloton-for-2-2bn/
Merck & Co’s Keytruda fails in triple negative breast cancer trialMost of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of Share XMerck & Co’s Keytruda fails in triple negative breast cancer trialhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-triple-negative-breast-cancer-trial/
Keytruda drives another strong Merck quarter, but what’s next?Merck & Co/MSD’s first quarter followed the predictable pattern of a surge in sales on the back of Share XKeytruda drives another strong Merck quarter, but what’s next?https://pharmaphorum.com/news/keytruda-drives-another-strong-merck-quarter-but-whats-next/
